- Home
- APRE vs ASBP Comparison
APRE vs ASBP Comparison
Compare APRE & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APRE | ASBP |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 7.6M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | APRE | ASBP |
|---|---|---|
| Price | $0.72 | $1.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.10 | N/A |
| AVG Volume (30 Days) | 216.2K | ★ 529.1K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.05 |
| 52 Week High | $2.22 | $2.45 |
Technical Indicators
Market Signals| Indicator | APRE | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 48.74 |
| Support Level | $0.55 | $0.20 |
| Resistance Level | $0.98 | $1.29 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 48.08 | 63.60 |
Price Performance
Historical ComparisonAbout APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.